Form Health

Form Health operates as a telehealth-focused obesity medicine practice serving patients throughout Massachusetts from its Boston headquarters, established in 2019 with board certification from the American Board of Obesity Medicine. The clinic delivers structured weight loss programs that combine GLP-1 receptor agonist medications with ongoing clinical oversight, specifically utilizing semaglutide, tirzepatide, and liraglutide as pharmaceutical interventions for patients meeting clinical criteria for obesity treatment. Each patient works with an assigned Care Team that includes prescribing clinicians credentialed in obesity medicine alongside registered dietitians who provide nutrition counseling tailored to individual metabolic profiles and lifestyle factors.

The medication protocols at Form Health center on incremental dosing strategies for GLP-1 therapies, with semaglutide and tirzepatide representing the primary peptide options for appetite regulation and glycemic control in eligible patients. Liraglutide serves as an alternative GLP-1 agonist for patients who require different dosing flexibility or have specific contraindications to the other medications. Clinical staff evaluate patients through comprehensive intake assessments that review medical history, current medications, weight loss goals, and any contraindications before prescribing these peptide therapies. The Boston-based medical team monitors patient progress through regular check-ins via the clinic's digital platform, adjusting medication dosages based on tolerance, side effect profiles, and weight loss trajectory over the treatment course.

Form Health's clinicians hold credentials in obesity medicine and maintain active licenses to prescribe controlled medications across state lines where telehealth regulations permit, with the Massachusetts-based practice serving as the administrative hub for clinical operations. The dietitians on staff provide evidence-based nutritional guidance that addresses macronutrient distribution, meal timing, and behavioral strategies to support the physiological effects of GLP-1 medications. This dual-provider model distinguishes the practice from single-clinician approaches, as patients receive both pharmacological management and nutritional counseling as integrated components of their treatment plan rather than as separate services.

Patients access Form Health entirely through telehealth appointments and a proprietary mobile application that facilitates messaging with care team members, tracks weight measurements, logs food intake, and provides educational resources about obesity pharmacotherapy. The digital-first model eliminates geographic barriers for Massachusetts residents seeking obesity medicine specialists, with video consultations replacing traditional in-office visits for medication management and progress evaluations. Prescription fulfillment occurs through partner pharmacies that ship medications directly to patients, with the care team coordinating insurance verification and prior authorization processes when applicable. The messaging system within the app allows patients to report side effects, ask questions about medication administration, or request guidance on nutrition challenges between scheduled appointments.

The clinic's approach to accountability involves scheduled weigh-ins, regular dietitian consultations, and clinician reviews at protocol-defined intervals throughout the treatment program. Form Health structures its programs around multi-month commitments that align with the timeline required for GLP-1 medications to demonstrate clinical efficacy, typically involving initial titration phases followed by maintenance dosing periods. The Boston practice emphasizes the role of these peptide therapies as tools within a broader obesity management strategy rather than standalone solutions, incorporating behavioral modification support and nutritional education as essential program elements that continue throughout the patient's enrollment.